Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Study Evaluating Vardenafil Compared to Placebo in Subjects With Erectile Dysfunction (ED) and Dyslipidemia

14 agosto 2017 aggiornato da: GlaxoSmithKline

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction and Dyslipidemia

This is a study consisting of four periods (screening, run-in, treatment, follow-up). A four-week treatment-free, run-in period where the subject will make at least four attempts at intercourse on four separate days with at least 50% of the attempts must be unsuccessful. During run-in the subjects will be using a stopwatch to measure the time from erection perceived hard enough for penetration until withdrawal from the partner's vagina. Next there are 12 weeks of treatment with either placebo or LEVITRA. Each subject will be required to visit the clinic on 5 occasions over a period of 4 months.

Panoramica dello studio

Stato

Completato

Tipo di studio

Interventistico

Iscrizione (Effettivo)

395

Fase

  • Fase 4

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Alabama
      • Fairhope, Alabama, Stati Uniti, 36532
        • GSK Investigational Site
      • Homewood, Alabama, Stati Uniti, 35209
        • GSK Investigational Site
      • Huntsville, Alabama, Stati Uniti, 35801
        • GSK Investigational Site
    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85016
        • GSK Investigational Site
      • Phoenix, Arizona, Stati Uniti, 85023
        • GSK Investigational Site
    • California
      • Concord, California, Stati Uniti, 94520
        • GSK Investigational Site
      • Huntington Park, California, Stati Uniti, 90255
        • GSK Investigational Site
      • Long Beach, California, Stati Uniti, 90806
        • GSK Investigational Site
      • Modesto, California, Stati Uniti, 95350
        • GSK Investigational Site
      • Newport Beach, California, Stati Uniti, 92660
        • GSK Investigational Site
      • Orangevale, California, Stati Uniti, 95662
        • GSK Investigational Site
      • Santa Ana, California, Stati Uniti, 92705
        • GSK Investigational Site
      • Walnut Creek, California, Stati Uniti, 94598
        • GSK Investigational Site
    • Colorado
      • Denver, Colorado, Stati Uniti, 80210
        • GSK Investigational Site
      • Wheat Ridge, Colorado, Stati Uniti, 80033
        • GSK Investigational Site
    • Connecticut
      • New Britain, Connecticut, Stati Uniti, 06052
        • GSK Investigational Site
    • Florida
      • Aventura, Florida, Stati Uniti, 33180
        • GSK Investigational Site
      • Clearwater, Florida, Stati Uniti, 33761
        • GSK Investigational Site
      • Coral Gables, Florida, Stati Uniti, 33134
        • GSK Investigational Site
      • Fort Myers, Florida, Stati Uniti, 33916
        • GSK Investigational Site
      • North Miami, Florida, Stati Uniti, 33161
        • GSK Investigational Site
      • Orlando, Florida, Stati Uniti, 32803
        • GSK Investigational Site
      • Pembroke Pines, Florida, Stati Uniti, 33024
        • GSK Investigational Site
      • Pinecrest, Florida, Stati Uniti, 33156
        • GSK Investigational Site
      • Saint Petersburg, Florida, Stati Uniti, 33710
        • GSK Investigational Site
      • Sarasota, Florida, Stati Uniti, 34237
        • GSK Investigational Site
      • South Miami, Florida, Stati Uniti, 33143
        • GSK Investigational Site
      • Tampa, Florida, Stati Uniti, 33607
        • GSK Investigational Site
      • West Palm Beach, Florida, Stati Uniti, 33401
        • GSK Investigational Site
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30342
        • GSK Investigational Site
      • Columbus, Georgia, Stati Uniti, 31904
        • GSK Investigational Site
      • Dawsonville, Georgia, Stati Uniti, 30534
        • GSK Investigational Site
      • Roswell, Georgia, Stati Uniti, 30076
        • GSK Investigational Site
      • Woodstock, Georgia, Stati Uniti, 30189
        • GSK Investigational Site
    • Indiana
      • Avon, Indiana, Stati Uniti, 46123
        • GSK Investigational Site
      • Evansville, Indiana, Stati Uniti, 47714
        • GSK Investigational Site
      • Fort Wayne, Indiana, Stati Uniti, 46825
        • GSK Investigational Site
      • Jeffersonville, Indiana, Stati Uniti, 47130
        • GSK Investigational Site
    • Kansas
      • Wichita, Kansas, Stati Uniti, 67207
        • GSK Investigational Site
    • Kentucky
      • Lexington, Kentucky, Stati Uniti, 40509
        • GSK Investigational Site
      • Madisonville, Kentucky, Stati Uniti, 42431
        • GSK Investigational Site
    • Louisiana
      • Shreveport, Louisiana, Stati Uniti, 71106
        • GSK Investigational Site
    • Maine
      • Swansea, Maine, Stati Uniti, 02777
        • GSK Investigational Site
    • Massachusetts
      • Taunton, Massachusetts, Stati Uniti, 02780
        • GSK Investigational Site
    • Michigan
      • Kalamazoo, Michigan, Stati Uniti, 49009
        • GSK Investigational Site
    • Minnesota
      • Saint Louis Park, Minnesota, Stati Uniti, 55416
        • GSK Investigational Site
    • Missouri
      • Saint Louis, Missouri, Stati Uniti, 63117
        • GSK Investigational Site
    • Nebraska
      • Omaha, Nebraska, Stati Uniti, 68134
        • GSK Investigational Site
    • Nevada
      • Las Vegas, Nevada, Stati Uniti, 89119
        • GSK Investigational Site
    • New Jersey
      • Lawrenceville, New Jersey, Stati Uniti, 08648
        • GSK Investigational Site
    • New York
      • New York, New York, Stati Uniti, 10016
        • GSK Investigational Site
      • Rochester, New York, Stati Uniti, 14609
        • GSK Investigational Site
      • West Seneca, New York, Stati Uniti, 14224
        • GSK Investigational Site
    • North Carolina
      • Charlotte, North Carolina, Stati Uniti, 28262
        • GSK Investigational Site
      • Fayetteville, North Carolina, Stati Uniti, 28304
        • GSK Investigational Site
      • Winston-Salem, North Carolina, Stati Uniti, 27103
        • GSK Investigational Site
    • Pennsylvania
      • Shippensburg, Pennsylvania, Stati Uniti, 17257
        • GSK Investigational Site
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37203
        • GSK Investigational Site
    • Texas
      • Amarillo, Texas, Stati Uniti, 79106
        • GSK Investigational Site
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84107
        • GSK Investigational Site
    • Virginia
      • Norfolk, Virginia, Stati Uniti, 23502
        • GSK Investigational Site
      • Richmond, Virginia, Stati Uniti, 23294
        • GSK Investigational Site
    • Washington
      • Seattle, Washington, Stati Uniti, 98166
        • GSK Investigational Site
    • Wisconsin
      • Menomonee Falls, Wisconsin, Stati Uniti, 53051
        • GSK Investigational Site
      • Milwaukee, Wisconsin, Stati Uniti, 53209
        • GSK Investigational Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 64 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Maschio

Descrizione

Inclusion criteria:

  • Males with ED for more than six months, according to the NIH Consensus Statement (inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance).
  • Stable heterosexual relationship for more than 6 months.
  • The subject must make at least four attempts at sexual intercourse (according to the question in the subject diary: Was sexual activity initiated with the intention of intercourse?) on four separate days during the untreated baseline period. At least 50% of attempts during this period must be unsuccessful, according to the following questions from the subject diary [at least one question should be answered "No"]: Were you able to achieve at least some erection (some enlargement of the penis)? Were you able to insert your penis into your partner's vagina? Did your erection last long enough for you to have successful intercourse?
  • Diagnosis of dyslipidemia treated with a stable dose of a statin for 6 months at Visit 1.
  • IIEF-EF domain score of 25 denoting mild to severe ED at Visit 2.
  • Documented, dated, written Informed Consent.

Exclusion criteria:

  • Premature ejaculator <2 minutes
  • Any unstable medical, psychiatric, spinal cord injury, penile anatomical abnormalities, or substance abuse disorder that MD feels subject will not be able to complete the study.
  • Low sexual desire.
  • Prior prostatectomy surgery
  • Severe chronic or acute liver disease, history of moderate or severe liver impairment
  • Clinically significant chronic hematological disease
  • Bleeding disorder or significant active peptic ulceration.
  • Cardiovascular conditions that prevent sexual activity.
  • History of heart attack, stroke, or life-threatening arrhythmia within the prior 6 months.
  • hypotension or hypertension at rest.
  • cancer within the past 5 years. Use of these medications: nitrates or nitric oxide donors, anti-androgens, oral or injectable androgens, received any investigational drug (including placebo) within 30 days of screening (Visit 1).
  • Use of any treatment for ED within 7 days of screening including oral medications, vacuum devices, constrictive devices, injections or urethral suppositories.
  • Subjects who are taking the following potent inhibitors of cytochrome P-450 3A4.
  • Abnormal Laboratory Values:

    1. serum total testosterone level >25% below the lower limit of normal
    2. serum creatinine >3.0 mg/dl.
    3. AST and/or ALT >3x the upper limit of normal.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore placebo: placebo
comparatore placebo
Comparatore attivo: Levitra
10mg x 4 weeks, with option to increase to 20mg aat that time if desired
active comparator

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Erectile function (EF) domain score of the International Index of Erectile Function (IIEF)
Lasso di tempo: Up to Week 12
The IIEF questionnaire is a validated 15-item instrument that assesses the participant's erectile function over the previous 4 weeks. The IIEF includes 5 domains affecting male sexual function: erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction. Responses to the IIEF were re-coded using a standard coding method, where more positive responses received a higher score. The EF domain score was calculated as the sum of the re-coded scores from questions 1-5 and 15, using last observation carried forward (LOCF). Scores range from 1 (lowest) to 30 (highest). If two or more items in the EF domain were missing, the EF domain score was considered to be missing.
Up to Week 12
Mean success rate of insertion based on attempts
Lasso di tempo: Up to Week 12
Success rate of insertion was derived from the Sexual Encounter Profile (SEP) Question 2 (SEP-2) of the participant's diary that asked 'Were you able to insert your penis into your partner's vagina?'. Responses were either Yes or No. Patients were instructed to complete diary questions as soon as possible after each sexual attempt, but no later than 24 hours after the attempt. The per-participant overall success rate for insertion was calculated by dividing the number of successful attempts (SEP-2=yes) over 12 weeks by the total number of valid attempts recorded over 12 weeks. If the participant was not able to make any valid attempts in 12 weeks, the participant was non-evaluable. Per-participant success rates were then averaged at the group level to obtain the mean success rate from Weeks 0-12.
Up to Week 12
Mean success rates of maintenance based on attempts
Lasso di tempo: Up to Week 12
Success rate of maintenance was derived from the SEP Question 3 (SEP-3) of the participant's diary that asked 'Did your erection last long enough for you to have successful intercourse?'. Responses were either Yes or No. Participants were instructed to complete diary questions as soon as possible after each sexual attempt, but no later than 24 hours after the attempt. The per-participant overall success rate for maintenance was calculated by dividing the number of successful attempts (SEP-3=yes) over 12 weeks by the total number of valid attempts recorded over 12 weeks. If the participant was not able to make any valid attempts in 12 weeks, the participant was non-evaluable. Per-participant success rates were then averaged at the group level to obtain the mean success rate from Weeks 0-12.
Up to Week 12

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Mean duration of erection leading to completion of successful intercourse as measured by Sexual Encounter Profile Question 3 [SEP-3]
Lasso di tempo: Up to Week 12
Duration of erection leading to completion of successful intercourse was derived from data recorded in the participant's diary. For each diary entry, the time from erection perceived hard enough for penetration until withdrawal from partner's vagina was measured by stopwatch and recorded in the participant's diary. For diary entries where SEP-3=yes, this recorded duration was used in calculations of a per-participant median duration. For diary entries where SEP-3=no, a duration of 0 was used to calculate the per-participant median. The per-participant median values averaged at the group level to obtain the mean duration of erection leading to completion of successful intercourse as measured by SEP-3.
Up to Week 12
Change from Baseline in scores for questions on the IIEF questionnaire and scores of the other non-EF domains of the IIEF
Lasso di tempo: Up to Week 12
Non-EF domains of the IIEF (Intercourse Satisfaction, Orgasmic Function, Sexual Desire, Overall Satisfaction) and IIEF questions (Erection during sexual activity?, Hard enough for penetration?, Able to penetrate partner?, Maintain your erection?, Maintain to completion?, Times attempted intercourse, Satisfactory for you?, Enjoyed sexual intercourse?, How often did you ejaculate?, How often feeling of orgasm?, How often felt sexual desire?, Rate level of sexual desire?, How satisfied with sex life?, Satisfied with sexual relationship? and Confidence to get, keep erection?) scores were assessed at Week 4, Week 8 and Week 12. The Baseline was the value at Week 0. Change from Baseline was the post-Baseline value minus Baseline value.
Up to Week 12
Number of participants with normal erectile function having EF domain scores of 26 and above
Lasso di tempo: Up to Week 12
The EF domain score was calculated by summing recoded responses to Questions 1-5 and 15, for each participant. It ranged from 1 to 30. EF domain scores were dichotomized as either normal (26 and above) or below normal (below 26) using LOCF, to calculate number of participants returning to normal erectile function. For the EF domain score the total was considered to be missing if 2 or more answers in the domain were missing.
Up to Week 12
Change from Baseline in participant's diary results
Lasso di tempo: Up to Week 12
Electronic diaries were provided to participants. Participants were supposed to complete the diary questions as soon as possible after each sexual attempt but no later than 24 hours after the attempts. The diary questions (Ability to achieve at least some erection, Ability to insert penis into partner's vagina, Long enough erection having successful intercourse, Satisfied with the hardness of erection, Satisfied with this sexual experience, Ability to ejaculate) response rates were presented for Weeks 0-12. The Baseline was the value at Week 0. Change from Baseline was the post-Baseline value minus Baseline value.
Up to Week 12
Mean duration of erection regardless of SEP-3 Response
Lasso di tempo: Up to Week 12
Duration of erection was time from erection perceived hard enough for penetration (start stopwatch) until withdrawal from the partner's vagina (stop stopwatch) regardless of completion of successful intercourse. The data was presented for overall period from Week 0 to Week 12.
Up to Week 12
Change from Baseline in duration of erection leading to completion of successful intercourse.
Lasso di tempo: Up to Week 12
Duration of erection was time from erection perceived hard enough for penetration (start stopwatch) until withdrawal from the partner's vagina (stop stopwatch) leading to completion of successful intercourse. The data was presented for overall period from Week 0 to Week 12. The Baseline was the value at Week 0. Change from Baseline was the post-Baseline value minus Baseline value.
Up to Week 12
Number of participants with response 'Yes' for Global Assessment Question
Lasso di tempo: Up to Week 12
The participants were asked to complete the self-administered Global Assessment Question. The question asked was 'has the treatment you have been taking over the past 4 weeks improved your erections'. The response was either Yes or No depending on comparison to participant's erections before their participation in this study. For the scale missing values remained missing.
Up to Week 12
Mean score for Keep It Simple (KIS) scale
Lasso di tempo: Up to Week 12
The KIS scale was a self-reported visual analog scale (VAS) from 0 to 10 designed to assess erections as 'how do you grade your erections over the last 4 weeks?'. For the scale missing values remained as missing.
Up to Week 12

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

22 maggio 2006

Completamento primario (Effettivo)

17 maggio 2007

Completamento dello studio (Effettivo)

17 maggio 2007

Date di iscrizione allo studio

Primo inviato

21 settembre 2006

Primo inviato che soddisfa i criteri di controllo qualità

21 settembre 2006

Primo Inserito (Stima)

22 settembre 2006

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 agosto 2017

Ultimo aggiornamento inviato che soddisfa i criteri QC

14 agosto 2017

Ultimo verificato

1 agosto 2017

Maggiori informazioni

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi